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DM complicating pregnancy is a common metabolic condition which attributes to 
congenital anomalies on fetus. Traditional Chinese medicine (TCM) has been used for 
thousands of years to treat diabetes mellitus (DM) in China. Both clinical and animal 
studies suggest that TCM can be as good as western medicine in the management of 
DM and could be more superior in treating diabetic complications, such as foot 
ulceration and nephropathy. 
Dwarf Lilyturf Tuber (Maidong) is one of the most commonly used TCM herb in DM 
treatment. However, the role of Maidong in DM complicating pregnancy is still 
uncertain, in particular, whether there is any protection on fetus in preventing 
hyperglycaemia induced congenital anomalies. 
In this thesis, three parts of experiments were designed. The potential efficacy and 
dose-effect response of Maidong extract, Maidong extract treated non-diabetic rat 
serum and Ophiopogonins D (a major chemical component ofMaidong) in preventing 
a common fetal anomaly in DM complicating pregnancy- cranial neural tube defect 
(cranial NTD) were explored separately by the whole mouse embryo culture in vitro. 
The results of the experiments indicated that: 
1. Maidong extract at dosages between 0.06mg/ml to 0.24mg/ml significantly 
attenuated the hyperglycemia induced cranial NTD in mouse embryos. Maidong 
extract at 0.06mg/ml resulted in the highest effectiveness but no obvious 
dose-response effect was determined. 
2. After 2 weeks oral administration to non-diabetic rats and the metabolized 
Maidong extract in rat serum protected the embryos from hyperglycemia induced 
cranial NTD. Within clinical dosage, Maidong extract offered a better protective 
V 
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effect than that at a higher dosage. 
3. The effective dosages of Ophiopogonin D in preventing hyperglycemia induced 
cranial NTD were between 0.5ng/ml to 1.5ng/ml. while a dosage of 0.5ng/ml 
offered the best protective effect. 
In conclusion, Maidong extract, Maidong extract-treated serum and Ophiopogonin D, 
a major component of Maidong, have therapeutic effect in preventing hyperglycemia 

































Background of diabetes mellitus and DM complicating pregnancy 
1.1 Definitions and clinical manifestations of Diabetes Mellitus 
Diabetes mellitus (DM) is a metabolic disorder which results from insulin secretion or 
insulin action defects. It presents as a chronic hyperglycemic condition with 
disturbances of carbohydrate, fat and protein metabolism (WHO, 1999). The typical 
clinical manifestations of DM include thirst, polyphagia, polyuria, blurring of vision 
and weight loss. 
1.2 Diagnostic criteria of DM 
According to the diagnostic criteria from World Health Organization (WHO), DM can 
be diagnosed by both clinical symptoms and plasma glucose level. Fasting plasma 
glucose greater than 7.0mmol/L or plasma glucose level higher than ll.lmmol/L 2hrs 
after a 75-g load oral glucose tolerance test (OGTT) can confirm the diagnosis of DM. 
If patients presenting the typical symptoms such as thirst, polyphagia, polyuria, 
blurring of vision or weight loss, diagnosis of DM can also be confirmed when venous 
plasma glucose level is greater than ll.lmmol/L (WHO, 2006). 
1.3 Classification of DM 
The latest classification of DM was revisited by WHO in 2006. The classification was 
based on the aetiology of DM and categorized DM into Type 1 diabetes mellitus 
(Type 1 DM), Type 2 diabetes mellitus (Type 2 DM), gestational diabetes mellitus 
(GDM) and other specific types of DM (WHO, 2006). Type 1 DM is caused by beta 
cell destruction which may result from autoimmune or idiopathic. It has early onset, 
especially on young people. Type 2 DM is due to insulin resistance with relative 
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insulin hyposecretion. GDM refers to DM is firstly detected in pregnancy. Other 
specific types of DM may due to genetic defects of insulin secretion or action, 
endocrinopathies, infections and so on. 
1.4 Prevalence of DM 
d m is rapidly increasing in most parts of the world. It was reported that there were 
246 million people worldwide confirmed having DM by 2007 (IDF, 2007) and the 
number is now estimated to increase to 438 million by 2030 (IDF, 2009). The 
published data from International Diabetes Federation in 2009 showed that the 
prevalence of DM ranged from 2.1% to 12% in Europe (WHO, 2004) while ranged 
from 5.2% to 30% in US (Cowie CC et al., 2006). In India, 40.9 million of people 
were reported having DM by 2007 (IDF, 2009). Over 3.8% of the adult population in 
Africa has been reported suffering from DM by 2010 (IDF, 2007). The prevalence of 
DM was 7.5% in Australians (Dunstan DW et al., 2002), 9 % in Japan by 2002 (MHL, 
2002), 7.6% in Korea (Kim SM et al., 2001), 5.5% in Mainland China (Gu D et al., 
2003) and 6.8% in Hong Kong (Chan NN et al., 2005) by 2001. 
The incidence of Type 1 DM varies a lot among populations, but it is generally 
increasing all over the world at an average rate of 3-4% per year (DIAMOND, 2006). 
The incidence of Type 2 DM increased worldwide very fast in the past 10 years, 
particularly in the regions with rapidly development of economics and urbanization. It 
is thought as a significant contribution to the increased prevalence of DM (Cowie CC 
et al., 2009). The onset age of Type 2 DM also decreases nowadays. More and more 
young adult develop Type 2 DM as the increase rate of obesity (IDF, 2009). 
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1.5 Aetiology and Pathogenesis of DM 
The cause of DM is complicate and likely to be multifactoral. Both genetic and 
environmental factors are implicated attributing to the incidence of the disease 
(Schranz DB & Lernmark A, 1998). Pathogenesis of DM is complicated. It includes 
resistance to insulin action or the pancreatic beta cells destroy which may 
consequently lead to insulin deficiency. Either insensitivity or hyposecretion of insulin 
may result in abnormal metabolism of carbohydrate, fat and protein and then develop 
DM (WHO 1999). Human leukocyte antigen (HLA) class II gene is reported 
responsible for inducing islet autoimmune response which may affect beta cell 
secretion and result in Type 1 DM (Thomson G et al., 2007). Both genetic and 
environmental factors play a role in inducing Type 2 DM by affecting insulin 
sensitivity (Gerich J, 1998). However, it is reported that Type 2 DM may also occur 
due to impaired beta cell function (Kahn S，2001) 
1.6 Treatment of DM 
Diet control is thought as the first line management throughout the development of 
DM (Riccardi G et al., 2000). It may help to restrict the intake of carbohydrate, fat 
and protein, as well as balance the energy in body to reduce the risk of hyperglycemia 
and avoid increase of body weight for DM patients (Stork ADM et al., 2006). Insulin 
is crucial for carbohydrate, fat and protein metabolism (Brogden RN & Heel RC, 
1987). It is the mainstay of treatment when a target blood glucose level is not 
perfectly achieved by diet control (Henry RR et al., 1993). Nowadays, oral 
hypoglycemic drugs are recommended as alternatives to insulin therapy as well. 
Different oral hypoglycemic drugs are selected according to their working pathway. 




(Bailey CJ et al., 2007; Natali A & Ferrannini E, 2006), sulfonylureas and 
meglitinides and gliptins are used for increasing insulin secretion (Groop LC, 1992; 
Garrino MG et al” 1985; Staels B & Fruchart J，2005), and alpha-glucosidase 
inhibitors are used to slow the carbohydrate metabolism (Lebovitz HE, 1998). 
1.7 Complications of DM 
Hyperglycemia results in long-term damage, dysfunction and failure of various organs 
and systems. Chronic hyperglycemia may adversely affect retina, renal glomerulus 
and peripheral nerves and then subsequently induce microvascular diseases such as 
diabetic retinopathy, diabetic nephropathy and diabetic peripheral neuropathy (Nathan 
D，1994). Besides, hyperglycemia may also accelerate atherosclerosis of the arteries 
in heart, brain and lower extremities and results in macrovascular diseases such as 
myocardial infarction, ischemic stroke and diabetic foot ulcer (Nathan DM et al” 
2005). 
1.8 DM complicating pregnancy 
Diabetic pregnancy can be generally classified into 2 types, DM complicating 
pregnancy and GDM. DM complicating pregnancy refers to the women with 
diagnosed Type 1 or Type 2 DM before conception, while GDM refers to the women 
who are firstly diagnosed with DM during pregnancy. 
1.8.1 Implications of DM complicating pregnancy 
d m complicating pregnancy has been increasing with the increasing incidence of 
Type 1 and Type 2 DM. It may result in series of maternal, fetal and neonatal 




have greater risk of pregnancy complications, such as preterm labour, hydramnios, 
pyelonephritis, hypertensive disorders, and so on (Domhorst A & Banerjee A, 2010). 
In addition, diabetic complications like retinopathy, nephropathy and neuropathy may 
occur as well (Domhorst A & Banerjee A, 2010). The fetus of diabetic mother is also 
at risk of congenital anomalies, macrosomia，intrauterine growth retardation, and 
intrauterine death. The offspring from the DM complicating pregnancy may suffer 
from hypoglycaemia, hypocalcaemia, asphyxia, respiratory distress, jaundice and 
cardiomyopathy (Edward J et al., 2000; Weindling AM, 2009; Simeoni U & Barker 
DJ, 2009). Clinical studies also strongly suggest that the offspring of diabetic mothers 
are at higher risk of obesity or Type 2 DM in their future life (Anne Domhorst, 2005). 
1.8.2 Diabetic Embryopathy 
Diabetic embryopathy refers to the morphogenesis at the end of blastogenesis and 
organogenesis (Anders Aberga, 2001; Chih-Ping Chen, 2005). A major threat to the 
fetus of a diabetic mother is life-threatening congenital anomaly. The data from the 
Confidential Enquiry into Maternal and Child Health (CEMACH) audit indicated that 
the prevalence of major structural congenital anomalies on the fetus from DM 
complicating pregnancy in UK was 41.8 out of 1000 births in 2003 (Modder J, 2005). 
It was 2-fold higher than the rate of the major structural congenital anomalies in 
non-diabetic pregnancies (Macintosh MC, 2006). 
1.8.3 Incidences of the major congenital anomalies 
Major DM induced congenital anomaly includes cardiovascular, musculoskeletal, and 
central nervous system (CNS) abnormalities (Martmez-Frfas ML, 1994; Aberg Aet al., 




arteries, truncus arteriosus and tricuspid atresia is as high as about 37.5%. It is 3-5 
folds higher than non-diabetic pregnancies (Wren C et al.，2003). There are 9.8% CNS 
anomalies including neural tube disclosure occurring in DM complicating pregnancy 
which is 2-10 folds higher than non-diabetic pregnancies (Shaefer-Graf UM et al., 
2000). The incidence of musculoskeletal system defect including talipes and 
arthrogryposis is reported as high as 14.8%, which is 2-20 folds higher than 
non-diabetic pregnancies (Shaefer-Graf UM et al” 2000). In addition, caudal 
regression syndrome is the relatively uncommon but typical congenital anomaly of 
DM embryopathy., The incidence is reported as 0.5%, which is 200 times higher in 
d m complicating pregnancy compared with non-diabetic pregnancies (NCCWCH, 
2008). 
1.8.4 Possible pathogenesis of congenital anomalies in DM complicating 
pregnancy 
The precise mechanism responsible for fetal teratogenesis in DM complicated 
pregnancy is unclear and is likely to be multifactoral. Animal studies on rodents 
indicate that glucose is the major teratogen in DM complicating pregnancy (Sadler 
TW, 1980; Moley K et al., 1996). Several capable pathways explored by laboratory 
studies in maternal hyperglycaemia induced teratogenicity were summarized as 
follow: 
1.8.4.1 Apoptosis 
Animal studies on rodents by Moley's group suggested hyperglycemia modified the 
expression of the key apoptotic regulatory genes and protein. Inhibition ofBcl-2 gene 
expression, increase of BAX and Caspase-3 protein due to hyperglycemia promoted 
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apoptosis of blastocysts. Reduced blastocysts formation resulted in early embryonic 
death and congenital anomalies (Moley KH, 1998). In addition, insulin treatment on 
rodents starting at conception in DM complicating pregnancy also showed a 
protective effect on normalizing the expression of apoptotic regulatory genes and 
preventing blastocysts reduction (Moley KH, 2001). These studies provided 
laboratory evidence that apoptosis might be one of the possible pathogenic pathways 
of hyperglycemia-induced congenital anomalies. 
1.8.4.2 Oxidative stress 
Maternal hyperglycemia may increase the concentrations of metabolic substrates 
(including glucose) and lead to oxidative stress. This could be another teratogenic 
factor of congenital anomalies in DM complicating pregnancy (Eriksson UJ & Borg 
LAH, 1993). Hyperglycemia at embryogenesis may result in an excessive generation 
of oxygen species and suppress the expression of gene (Pax-3). The function ofPax-3 
gene is to downregulate p53 protein which is the cause of neutral tube apoptosis (Pani 
L et al., 2002). Therefore, the increase of p53 protein which is secondary to the 
suppression of Pax-3 gene consequently promotes neural tube apoptosis and results in 
NTD. In addition, using of anti-oxidants was proven to diminish both embryonic 
dysmorphogenesis induced by hyperglycemia (Wentzel P & Eriksson UJ, 1998). This 
may help to imply that hyperglycemia-induced oxidative stress is a plausible pathway 
resulting in congenital anomalies. 
1.8.4.3 Arachidonic acid and PGE2 
Decreased level of arachidonic acid and PGE2 has been implicated as one of the 




experiments by Eriksson's group demonstrated that hyperglycemia during the period 
of neural tube closure reduced arachidonic acid and embryonic PGE2 levels. The 
subsequent down regulation of embryonic COX-2 gene then resulted in NTD in the 
rat embryos (Eriksson UJ et al, 2003). However, injections of arachidonic acid on 
diabetic rats showed arachidonic acid had therapeutic effect on reducing the rates of 
NTD. It could be the evidence that the pathological decrease of arachidonic acid 
might induce NTD in DM complicating pregnancy (Pinter E et al” 1986). 
1.8.5 Clinical management of DM complicating pregnancy 
As maternal hyperglycemia is recognized as a major teratogen in DM complicating 
pregnancy, pre-pregnancy care and antenatal managements on glycemic control are 
important for preventing the subsequent congenital anomalies. 
1.8.5.1 Pre-pregnancy care 
Women with DM are recommended to achieve a glycemic target before conception 
which is assessed by HbAic. HbAic is a diagnosis test of blood glucose level. It is 
required to be performed at 3 month intervals on DM women before starting 
pregnancy. Women with pre-existing DM are recommended to start pregnancy only 
when the HbAic is lower than 53mmol/ml (Jensen DM et al., 2009). Moreover, a 
folate riched diet and a dose of 5mg folic acid are recommended starting before 
conception until the 12 weeks of pregnancy for the women with DM complicating 
pregnancy to reduce the risk of NTD on fetus (MRC, 1991). Appropriate diet and 
exercise are also helpful for blood glucose control. Screening for the possible DM 
complications such as retinopathy and nephropathy before pregnancy is important as 
well (Modder J, 2007). Proper treatments can be started before pregnancy rather than 
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during pregnancy in order to minimize the possible adverse effect on fetal 
development. 
1.8.5.2 Antenatal management of DM complicating pregnancy 
Obstetric care and diabetic management should be combined for DM complicating 
pregnancy. Monitoring on blood glucose level is required throughout pregnancy for 
the women with DM complicating pregnancy. Glycemic target for a diabetic mother is 
followed a national guideline for all types of DM complicating pregnancy. The current 
guideline are set as fasting blood glucose level ranges from 3.5 to 5.9mmol/L and 1 
hour post-prandial blood glucose lower than 7.8 mmol/L (GDG, 2008). The main 
steps in the management of DM complicating pregnancy are similar to the 
management of DM, which lie in diet control, insulin therapy and oral hypoglycemia 





Background of Traditional Chinese Medicine in treatment of DM 
Traditional Chinese Medicine (TCM) has been used for thousands of years to treat 
DM in China and some other Asian countries. There is abundant experience of TCM 
in the management of DM and its complications (Li WL et al., 2004). 
2.1 Definition and manifestations of DM in TCM theory 
In TCM theory, DM is recognized as "Wasting Thirst" ("Xiao Ke",消渴).The 
typical clinical manifestations of DM were described as "three increases and one 
decrease (三多一少)，，，which refers to thirst, polyphagia, polyuria and weight loss 
(Zhang H et al, 2010). Other clinical presentations of DM may include sweet urine, 
lassitude, warm feeling in palms, soles and chest, afternoon fever, night sweating, 
dizziness, blurred vision, palpitation, insomnia, normal defecation of constipation, red 
tongue with little or yellow coating，thread and rapid pulse (Zhang ZL, 2007). 
2.2 Historical context of DM in TCM 
Based on the literatures about TCM, there are 5 important milestones about the 
understandings and management of DM in the history of TCM. 
2.2.1 Spring and Autumn Period and Warring States Period (770 B.C.—8 A.D.)： 
the first nomenclature of "Wasting Thirst" 
The earliest literature about DM was recorded in the most famous and authoritative 
work in TCM named “Canon of Yellow Emperor"(《黃帝內經》475 B.C.-8 A.D.). In 




(Shen LY, 2004). In this book, DM was firstly defined as "Wasting Thirst" ("Xiao 
Ke”，消渴)and the typical clinical presentations of DM was described as “three 
increases and one decrease" (Zhang H et al, 2010). In addition, the possible 
aetiologies of DM were also mentioned in this book and elaborated as obesity and the 
inappropriate intake of sweet and greasy food. Apart from the nomenclature, this book 
also recorded a herbal plant, Eupatorium Fortunei (Lancao,蘭草)，which had 
therapeutic effects on DM. It was firstly revealed that DM could be treated by herbal 
medications (Shen LY, 2004). After this, more herbal medications have been explored 
and used for curing DM for more than 2000 years in China. 
2.2.2 Han Dynasty (9 A.D•-280 A.D.)： monograph on "Wasting Thirst，， 
Zhongjing Zhang was one of the famous TCM practitioners in Han Dynasty in 
Chinese history. He was a pioneer on studying DM and innovatively published a 
specialized chapter (《消渴小便不利淋病脈證並治第十一》）about DM in his 
authoritative medical work "Golden Chamber，’（“Jin Kui Yao Lue，，，《金匱要略》）. 
Nine formulae as treatments of DM were recorded in this book and categorized by 
symptoms and pathogenesis of DM，such as Bai Hu Jia Ren Shen Tang (白虎力口人參 
湯)，Shen Qi Wan (賢氣九)，and Wu Ling San (五茶散）(Zhang H et al, 2010). Most 
of these formulae are still popular to use in clinical practice today. 
2.2.3 Sui and Tang Dynasty (581 A.D.-960 A.D.)： the diagnosing marker of 
"Wasting Thirst" 
In Sui Dynasty (581 A.D. - 618A.D.)，TCM practitioner Liyan Zhen recorded "Sweet 
Urine"(尿甜)as a diagnostic marker of DM in his book "Ancient and Modem Proved 
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Formulae" ("Gu Jin Lu Yan Fang",《古今錄驗方》)(Zhang H et al, 2010). It was the 
earliest record which revealed DM was related to the dysfunction of glucose 
metabolism. It was 1200 years earlier than the German physiologist Minkowski and 
Von Mering discovered that urine of DM patient tastes sweet in 1889 (Ding XP, 2004). 
In addition, a more detailed description of DM symptoms was recorded in this book as 
follow: "Excessive drinking due to thirst, frequent urination with fat free, sweet taste 
and bran-like urine"( “渴而飲水多，小便數，無脂似魅片甜者，皆消渴病也。”). 
Another authoritative work on DM in this period was "Medical Secrets of Official" 
(“Wai Tai Mi Yao”，《外台秘要》）.It was written by Tao Wang in 752 A.D. This book 
summarized most of the understandings and clinical experiences about DM before 
Tang Dynasty (Dengben Z, 2004). It was one of the most outstanding books of TCM 
in diabetology. 
Simiao Sun, the most greatest TCM practitioner in Tang Dynasty (581- 682 A.D.)， 
described the toxicity of alcohol in resulting DM in his famous medical books, 
"Essential Prescriptions Worth A Thousand Gold，，（“ Bei Ji Qian Jin Yao Fang",《備 
急千金要方》）and “The Revision of Essential Prescriptions Worth A Thousand Gold" 
("Bei Ji Qian Jin Yi Fang",《備急千金翼方》）（Ding XP, 2004). Apart from herbal 
medications, non-medicinal managements of DM were mentioned in his book as well 
(Lin Q & Wang MQ, 2000). 
2.2.4 Song Dynasty (960 A.D.-1270 A.D.) : the Golden Time of developing the 
treatment on DM 
Enlightened by the theory ofZhongjing Zhang, Wansu Liu (1120 A.D.-1200 A.D.), a 




history which was called “Theory of Three Categories of Wasting Thirst" (San Xiao 
Lun,三消論）（Lin Q & Wang MQ, 2000). This theory categorized DM into three 
types based on the pathogenesis. These three types of DM were “Upper Wasting 
Thirst" (Shang Xiao,上消)，"Middle Wasting Thirst” (Zhong Xiao,中消)，and 
"Lower Wasting Thirst" (Xia Xiao,下消).The pathogenesis and treatment of each 
type of “Wasting Thirst" are summarized as follow: 
1. "Upper Wasting Thirst” 
(1) Pathogenesis: One of the function of the "Lung (肺)，，is to distribute the “Body 
Fluid (津液)’，.The “Asthenic Heat (虛熱)，，due to “Yin Deficiency (陰虛)，，may 
impact the normal function of the "Lung" and resulting in "Body Fluid" 
distribution failure, which presents as polyuria and thirst. 
(2) Principles of treatment: clearing "Asthenic Heat" and promoting "Body Fluid" 
production; moistening the "Lung" and quench one's thirst (清熱潤肺，生津止渴） 
(3) Formula: Xiao Ke Fang (消渴方） 
(4^ Composition of the formula: Rhizoma Coptidis (Huanglian,黃連)，Radices 
Trichosanthis (Tianhuafen，天花粉)，Breast milk (乳汁)，Juice of Lotus Root (蓮 
藕汁)，Juice of Radix Rehmanniae (Shengdihuang,生地汁)，Juice of Ginger (生薑 
汁),Honey (蜂蜜） 
2. "Middle Wasting Thirst" 
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(1) Pathogenesis: The normal function of the "Spleen (脾)，，and the "Stomach (胃)，，in 
digesting and transporting the "Essential Nutrients (7jc穀精微)” are impacted by 
the "Asthenic Heat”. Therefore, polyphagia and weight loss occur. 
(2) Principle of treatment: clearing “Asthenic Heat" in “Stomach”，tonifying "Yin (陰)” 
and promoting "Body Fluid” production (清胃瀉火’養陰生津). 
(3) Formula: Yu Nv Jian (玉女煎） 
Composition of the formula: Ophiopogonis Radix (Maidong,麥冬)，Radix 
Rehmanniae (Shengdihuang,生地黃)，Radix Scrophulariae (Xuanshen，玄參)， 
Gypsum (Shigao,石膏)，Radices Trichosanthis (Tianhuafen,天花粉)，Rhizoma 
Coptidis (Huanglian，黃連），Gardenia Jasminoides (Zhizi,梔子），Rhizoma 
Anemarrhenae (Zhimu, ^pg), and Radix Achyranthis Bidentatae (Niuxi，牛膝). 
3. "Lower Wasting Thirst" 
(1) Pathogenesis: The "Kidney (腎)’，is the ‘‘Essential Origin (先天之本)” of human 
body. Deficiency of “Kidney-Yin (腎陰)，，results in "Yin Deficiency" of the body 
and generate the "Asthenic Heat". When the "Asthenic Heat" impacts the function 
of the "Lung" and the "Heart (/(>)，，，it presents as thirst. When the “Asthenic Heat" 
impacts the ftinction of the "Spleen" and the "Stomach", it presents as polyphagia. 
The "Kidney" may also lose its control on urine production and emotion due to the 
deficiency of "Kidney-Yin". Therefore, frequent urination and abnormal glucose 
level in urine happens. 
(2) Principles of treatment: Tonifying "Yin" and benefiting the "Kidney"(滋陰益腎). 
(3) Formula: Liu Wei Di Huang Wan (六味地黃九). 
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Composition of the formula: Radix Rehmanniae (Shengdihuang,生地黃）， 
Dioscorea Polystachya Turcz (Huaishanyao,淮山藥），Cornus Officinalis 
(Shanzhuyu,山茱舆)’ Cortex Moutan Radicis (Mudanpi，牡丹皮)’ Rhizoma 
Alismatis (Zexie,澤寫)，and Poria (Fuling,获爷). 
2.2.5 Ming and Qing Dynasty (1270 A.D. -1911 A.D.) : the integration period of 
TCM theory on DM 
Western mediciiie (WM) was introduced to China since Ming Dynasty. The 
understanding of DM was strongly improved in this period. Xichun Zhang (1860 
A.D. -1933 A.D.) was a pioneer in integrative medicine both on TCM and WM in 
Late Ming dynasties. He wrote a whole chapter named “Therapies of Wasting Thirst" 
(“消渴篇”）in his book “The Integration of Traditional Chinese Medicine and Western 
Medicine,，("Yi Xue Zhong Zhong Can Xi Lu，,，《醫學衷中參西錄》）.The definition, 
possible pathogenesis, diagnosis, treatment, prevention approaches as well as some 
clinical case records of DM were well elaborated both on TCM and WM theory (Lin 
SZ，2008). In addition, Xichun Zhang was recognized as the first person in Chinese 
history to combine TCM and WM in the management of DM (Hao XZ, 2008). 
2.3 Aetiology of DM in TCM theory 
TCM theory bases on "Yin Yang Theory (陰陽學說)”，“Five Elements Theory (五行 
學說)”，and “Zang Fu Theory (臟腑理論)”.It focuses on the balance of “Yin (陰)，’， 
“Yang (隠)”，“Qi (氣)”，"Blood (血)”，"Body Fluid (津液)，,.When any of these 
balances is broken, disease happens. Therefore, the aeotiology of DM can be 
summarized in the following 4 aspects (Ding XP，2004): 
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2.3.1 Congenital weakness 
The "Kidney" is the "Essential Origin” of human body. "Kidney Deficiency" is 
common in people bom with "Congenital Weakness"(先天稟賦不足)’ In "Kidney 
Deficiency", the "Kidney" cannot function well to support the "Lung" and then result 
in "Lung Deficiency (肺虛)，，.The “Lung” fails to distribute "Body Fluid" due to its 
deficiency. Most of the “Body Fluid" flows to the “Bladder (膀胱)，，and results in 
polyuria. Hence, there is not sufficient "Body Fluid" to supply the "Essential Yin (元 
• ) ” in the "Kidney", which lead to systemic "Yin Deficiency" of the body. When the 
“Asthenic Heat" secondary to "Yin Deficiency" rises upward and torches the "Heart" 
and the “Lung，，，it causes dysphoria and polydypsia (Yin XC, 2005). When it torches 
the "Spleen" and the "Stomach", it leads to polyphagia and affects the normal 
function of the "Spleen" which are digesting and transporting the "Essential Nutrients" 
from daily food and drink. In this way, the "Essential Nutrients" flow to the urine 
without being metabolized by the "Spleen" and the "Stomach,，，which makes the urine 
taste sweet. Since the most of the "Essential Nutrients" flow to urine, there is not 
enough nutrition to supply muscles, which leads to muscle emaciation and presents as 
weight loss. 
2.3.2 Improper diet 
Addicting to alcohol or overeating of greasy, sugar and fat enriched food may lead to 
malfunction of the "Spleen". Malftinction of the "Spleen" in digesting and 
transporting the "Essential Nutrients" results in "Retention of Phlegm-Damp"(痰濕 
潴留）in the body. "Retention of Phlegm-Damp" is one kind of inappropriate 
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distribution of the "Body Fluid" which may result in polyuria and thirst. 
2.3.3 Emotional disorders and overstrain 
The incidence of DM is closely related to emotional disorders and irregular eating and 
sleeping. Nowadays, people suffer much more stress from work and family life than 
the old days. Based on the TCM theory, emotional disorder torches the "Spleen" most. 
Stagnation of "Qi" due to anxiety, anger, depression and other emotional disorders 
attacks the "Spleen". Since the "Spleen" is in charge of digesting and transporting the 
"Essential Nutrients" from food and drink and then transforms them to "Qi"，“ Blood" 
and "Body Fluid" to maintain the normal body function. Therefore, when the "Spleen" 
is disturbed by emotional factors, "Qi”，"Blood" and "Body Fluid" will lose their 
deprivation origin and result in ‘‘Yin Deficiency" which may induce DM. In addition, 
the "Endogenous Fire”（內火）due to the stagnation of "Qi，，may also consume the 
"Yin" and induce or aggregate DM. 
2.3.4 Excessive sexual activities 
The "Kidney" is the "Essential Origin" of the body. Excessive sexual activities give 
great burden to the "Kidney". It consumes the "Essential Yin" of the "Kidney" and 
results in systemic "Yin Deficiency" of the body. The "Asthenic Heat" due to "Yin 
Deficiency" influences the normal function of organs and disturbs the distribution of 
the "Body Fluid", and then induces DM. 
2.4 Pathogenesis of DM in TCM theory 
"Yin Deficiency" is the basic pathogenesis and goes through the whole process of DM. 
DM has miscellaneous etiologies. Although nowadays some other pathogeneses such 
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as "Dual Qi-Yin Deficiency"(氣陰兩虛)，blockage of collaterals by "Blood Stasis (游 
血)"，and “Dual Spleen-Kidney Yang Deficiency”（脾腎陽虛）(Yin XC, 2005) are 
reported, the key pathogenesis attributes to DM always lies in "Yin Deficiency" and 
the consequent pathogen, “Asthenic Heat". The “Asthenic Heat" secondary to "Yin 
Deficiency" impacts the normal function of the "Lung", the "Spleen" and the "Kidney" 
("Three Waste Thirst Theory") and results in thirst, polyphagia, polyuria and weight 
loss. 
As mentioned above, the "Kidney" is the essential origin of the body. Both congenital 
weakness and excessive sexual activities may induce "Kidney Deficiency" and 
malfunction of the "Kidney". If the "Kidney" could not ftinction well to support the 
"Lung", it may lead to subsequent “Lung Deficiency". The "Lung" fails to distribute 
the "Body Fluid" due to its deficiency. Then the "Body Fluid" flows to "Bladder" 
directly without nourishing other organs and then resulting polyuria. Lacking of 
"Body Fluid" to supply the "Essential Yin" of the "Kidney" may lead to systemic 
"Yin Deficiency" of the body. In addition, malfunction of the "Spleen" due to eating 
and emotional disorders may lead to "Qi", "Blood" and "Body Fluid" loss from their 
deprivation origin and results in "Dual Qi-Yin Deficiency". Subsequently stagnation 
of "Qi" due to emotional problem may also generate the "Endogenous Fire" in the 
body which may consume "Yin" and lead to “Yin Deficiency". 
Based on the balance of "Yin" and “Yang，，，"Yin Deficiency" may result in the 
excessive rise of "Yang", which presents as the subsequent "Asthenic Heat". The 
"Asthenic Heat" may consume the "Body Fluid", disturb its normal distribution and 
influence the normal function of organs. If "Asthenic Heat" ascends upward and 
torches the "Lung", it may lead to thirst. If it torches "Spleen" and "Stomach", it may 
lead to polyphagia. Besides, the "Essential Nutrients" flow to the urine without being 18 
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metabolized by the “Spleen，，and the "Stomach". It makes the urine taste sweet while 
lacking of enough nutrient supply to other part of the body may lead to weight loss. 
Moreover, malfunction of the "Spleen" in digesting and transporting the "Essential 
Nutrients” may results in "Retention of Phlegm-Damp" in the body. Excessive 
accumulation and failure to distribute the "Body Fluid" may attribute to polyuria and 
polydypsia. Besides, long time “Retention of Phlegm-Damp" may impair the 
movement of "Qi" and generate the “Endogenous Fire" which consumes the “Body 
Fluid" and finally result in thirst. 
2.5 Prognosis of DM in TCM theory 
2.5.1 “Dual Qi-Yin Deficiency" and “Dual Yin-Yang Deficiency" 
Apart from the impairment of “Body Fluid", the “Asthenic Heat" due to “Yin 
Deficiency" may also consume "Qi" and result in "Dual Qi-Yin Deficiency，，(Zhang 
ZL, 2007). In addition, based on the "Yin-Yang Theory", "Yin" and “Yang，，can 
deprives one another. Therefore, as the disease progresses, persistent "Yin Deficiency" 
may impair “ Yang" and result in "Dual Yin-Yang Deficiency (陰陽兩虛)，’.Since "Yin" 
and "Yang" are crucial to human life, "Dual Yin-Yang Deficiency" may lead to poor 
prognosis of DM (Ding XP, 2004). 
2.5.2 Multi-systemic malfunction of "Zang Fu，， 
At the onset of the DM, the disease mainly affects the "Lung", the "Spleen" and the 
"Stomach". Along with the development of the disease, the "Kidney" and other 
organs are involved (Ding XP, 2004). Systemic malftinction of organs may lead to 
multi-system manifestations and result in poor prognosis. 
19 
Y Tong 
2.6 Principle of treatment 
According to TCM theory, "Yin Deficiency" is the principal aspect (本）of the DM 
pathogenesis, while “Asthenic Heat" is the secondary aspect (標).Therefore the 
treatment of DM in TCM is carried based on tonifying ‘‘Yin”（滋陰）and clearing the 
"Asthenic Heat”（清熱)• 
2.7 Commonly used herbal remedies and recent experimental studies 
Herbal remedies are the most commonly used therapy in TCM. Over hundreds of 
herbs have been used to treat DM as herbal remedies during the thousands of years' 
TCM clinical practice. Clinical studies suggest 33 TCM herbs which are the most 
frequently used in treatment of DM and its complications. These herbs include 
Ophiopogonis Radix (Maidong,麥冬)，Rehmanniae Radix (Shengdihuang,生地黃)， 
Radix Ginseng (Renshen,人參），Trichosanthes Radix (Tianhuafen,天花粉）， 
Astragali Radix (Huangqi,黃民)，Coptidis Rhizoma (Huanglian，黃連)，Polygonati 
Yuzhu Rhizoma (Yuzhu,玉竹）and so on (Li WL et al., 2004). These herbs can tonify 
"Yin", clear "Asthenic Heat" and help to produce the "Body Fluids". Among the 
commonly used herbs stated above, Ophiopogonis Radix (Maidong,麥冬)，Radix 
Ginseng (Renshen,人參)，Astragali Radix (Huangqi,黃民)，Polygonati Yuzhu 
Rhizoma (Yuzhu,玉竹)，and Coptidis Rhizoma (Huanglian,黃連）are reported given 
priority for selection as medicinal treatment and have therapeutic effect on decreasing 
blood glucose level by animal experiments (Sotaniemi EA et al., 1995; Chan JYW et 
al., 2008; Wu L et al, 2007; Jong MH et al., 2007). 
Compared with single herb, formula are more popular used as medication in clinical 




煎)，Sha Shen Mai Dong Tang (沙參麥冬湯），Liu Wei Di Huang Wan (六味地黃九)， 
Xiao Ke Fang (消渴方），Huang Lian Di Huang Tang (黃連地黃湯），Bai Hu Jia Ren 
Shen Tang (白虎加人參湯），Zhu Ye Shi Gao Tang (竹葉石膏湯）and so on (Ding XP, 
2004). 
In addition to the single herbs and formulae, the anti-hyperglycemic effect of the 
chemical components isolated from raw herbs has been explored as well. Based on 
animal studies, chemical compounds including polysaccharides (Wu SJ & Li DY, 
1992)，terpenoids, flavonoids (Gu GY & Jiang Y, 1997), sterols and alkaloids (Yin J 
& Chen MD, 2000) isolated from raw herbs have been reported having therapeutic 
effect on glycemic control. 
2.8 TCM on relieving DM complications 
WM is well established and proven safe and effective in treating DM, especially in 
controlling the blood glucose level. As a different therapy, TCM shows great potential 
in treating DM complications in clinical practices. Both clinical and animal studies 
show TCM are effective in preventing or relieving the DM complications such as 
diabetic neuropathy (Abuaisha B, 1998), diabetic retinopathy (Luo XX et al., 2009; 
Liang XC et al, 2002), diabetic foot ulcer (Li SF, et al, 2011), and diabetic nephropathy 
(Zhou XJ, 2003). Moreover, TCM are also reported more effective in reducing blood 
glucose level, relieving DM symptoms and preventing diabetic complications when 
used in combination with WM (Cheng HQ et al., 1998). 
2.9 Dwarf Lilyturf Tuber (Ophiopogonis Radix, Mai Dong,麥冬） 
"Yin Tonics"(滋陰藥）is a category of TCM which can tonify "Yin" and promote the 
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production of the "Body Fluid"(滋陰生津).They are commonly used as a DM 
regime to reduce the impairment of the “Body Fluid" due to “Yin Deficiency". Dwarf 
Lilyturf Tuber {Ophiopogonis Radix, Maidong,麥冬）is one of the most commonly 
used "Yin Tonics" in TCM. This herb consists of the tuberous root of the Perenital 
Herbagte Ophiopogon japonicus (LF.) Ker-Gawl (Zhao AQ，2004). It is "Sweet to 
taste (味甜)，，and "Cold in nature (性涼)，,.The therapeutic potentials of Maidong is 
tonifying "Yin,’ and clearing away "Asthenic Heat"(滋陰清熱)，moistening the 
"Lung" and "Stomach" and then promoting the “Body Fluid" production (滋養肺胃， 
生津潤燥).It has been reported that Maidong was effective on glycaemic control in 
DM patients (Zhang WX & Wang NH, 1993). 
Ophiopogonins and polysaccharides are two major chemical components of Maidong 
which contribute the therapeutic effect on glycaemic control (Yang MP et al., 2008). 
Known ophiopogonins of Maidong are ophiopogonins A，B, C and D which belong to 
Ruscogenin，and ophiopogonins B，，C，，D，which belong to Diosgenin. Md-1 and 
Md-2 are the two known polysaccharides in Maidong (Cheng ZH et al, 2005). 
2.10 Objectives and hypothesis 
2.10.1 Objectives 
Dwarf Lilyturf Tuber {Ophiopogonis Radix, Maidong,麥冬）is one of the most 
commonly used TCM herb in DM treatment (Zheng H, 2008). However, the role of 
Maidong in DM complicating pregnancy is still uncertain, in particular, whether there 
is any protective effects on fetus in preventing hyperglycaemia induced congenital 
anomalies. In this thesis, we aimed to investigate whether Maidong is effective in the 





Following hypothesizes were examined in this thesis: 
1. Maidong at clinical dosage are safe for embryo development at early stage of 
pregnancy. 
2. Maidong and its major components have protective effect in preventing 





Methodology and Results 
Whole embryo culture (WEC) system was employed to study the embryotoxicity and 
potential efficacy of Maidong on cranial neural tube defect (cranial NTD) induced by 
hyperglycemia in vitro. 
3.1 Set up of mouse embryos 
3.1.1 Mouse strain 
Non-diabetic female Institute of Cancer Research (ICR) mice provided by Laboratory 
Animal Service Center of the Chinese University of Hong Kong (LASEC, CUHK) 
were used in this study. Pregnant ICR mice were sacrificed on day 7.5 of gestation 
(E7.5) and the embryos were isolated for whole mouse embryo culture. 
3.1.2 Research animal ethics and care guidelines 
Animal Ethics (08/011/ERG & 09/015/GRF) were obtained for all laboratory animal 
experiments. In this study, all mice were kept on a 12:12 hrs light-dark cycle with 
light period from 6:00 am to 6:00 pm in the animal house in Prince of Wales Hospital 
with constant temperature at 25 °C. 
3.1.3 Mating and sacrifice of ICR mice 
Female ICR mice were mated with non-diabetic male ICR mice overnight. Pregnancy 
was confirmed by checking vaginal copulation plug on female mice in the morning of 
the next day after mating. Fertilization was assumed to occur at midnight. The noon 




Non-diabetic ICR mice at E7.5 were sacrificed by cervical dislocation. Uterus was 
removed by sterilized forceps and scissors after abdominal dissection. 
3.1.4 Embryo dissection and grouping 
Uterus was immersed in 37°C treated PBl medium with Fetal Bovine serum (FBS) 
mixture to keep the embryos alive during dissection. Uterus was separated under 
microscope. Deciduas and Reichert's membrane of the embryos were removed 
separately. The developmental stages of the embryos were evaluated and confirmed. 
Only non-damaged mouse embryos at the desired developmental stage of E7.5 were 
selected for culture (Fig. 3.1). Embryos were divided into control group and study 
group at random in all the experiments. Every 4 embryos were cultured in a single 
glass culture bottle. 
3.2 Preparations of D-glucose 
D-glucose in fine powder form was obtained from Sigma-Aldrich Co. Ltd. Analytical 
methods by High-performance liquid chromatography (HPLC) shows the purity of 
this product is higher than 99%. In this study, D-glucose at ascending dosages was 
supplemented to the embryos in culture medium to determine the most optimal 
concentrations to produce a hyperglycemic environment sufficient to induce cranial 
NTD in the mouse embryos. 
3.3 Chinese medicine quality controls and preparations 
Maidong extract in concentrated granules form (Ig Maidong extract = 3g Maidong 
raw herb) was obtained from PuraPharm International (HK) Ltd. The extract was 
prepared in Good Manufacturing Practices (GMP) standard. HPLC was used for 
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chemical authentication to ensure the quality and to avoid any pesticide, mineral and 
other biological contaminations on the extract. This product are provided for clinical 
use in most local TCM clinics and sold in pharmacies in Hong Kong. 
3.4 Whole mouse embryo culture 
Whole mouse embryo culture system is well established to demonstrate the 
teratogenicity and embryotoxicity of indicated drug or chemicals. It observes 
embryogenesis from early gastrulation to early organogenesis stages (E7.5 to E9.5) 
(Fig. 3.1). Cranial NTD is a major congenital anomaly during this period (Nagy & 
Andras, 2003). 
r , ^ ^ 
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Fig. 3.1 Mouse Embryos at different gestational stages after in vitro culture 
D-glucose was dissolved into the culture medium to create a hyperglycemic 
environment to induce cranial NTD in the mouse embryos as a positive control. 
Maidong extract was supplemented to the embryos in culture medium with D-glucose 
to determine the possible protective effect ofMaidong on embryo development. 
Full rat serum was used as the culture medium. It was firstly heat-treated at 56°C for 
30 minutes to inactivate the compliments. Then, D-glucose powder or Maidong 
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extract was dissolved into the heat-treated full rat serum and well mixed before using 
to cultivate the embryos. 
D-glucose with or without Maidong extract was dissolved in non-diabetic full rat 
serum in the rotor bottle culture incubator (Precision Incubator 317, B.T.C. 
Engineering, Milton, Cambridge, UK). Isolated embryos at E7.5 were then cultivated 
in it for up to 48 hours at 37°C with continuously aerated oxygen, carbon dioxide and 
nitrogen gas mixtures. Different ratio of oxygen and carbon dioxide were supplied at 
different time points. In the first 24 hours, 5% oxygen, 5% carbon dioxide and 90% 
nitrogen were provided. In the following 8 hours, 20% oxygen, 5% carbon dioxide 
and 75% nitrogen were supplied. In the next 16 hours of culture, 40% oxygen, 5% 
carbon dioxide and 55% nitrogen were used. All gas mixtures were supplied by Hong 
Kong Oxygen Ltd., which safety and quality were confirmed. 
3.5 Morphological scoring on mouse embryos and statistical analysis 
After 48 hours culture, embryos were harvested at E9.5. Then, the developments of 
fore-, mid- and hind-brain of the embryos were assessed under microscope. Brown 
and Fabro morphological score system was used to assess the development of fore-, 
mid- and hind-brain of the embryos at E9.5 after the embryo culture (Brown NA & 
Fabro S, 1981). Detailed assessment of scoring system is shown as follow: 
1. Forebrain: 
Presenting of only neural plate was recorded as score 0. Presenting a V-shape of 
neural folds in tangential view was recorded as score 1 • The edge of the neural tube 
became closer and presenting a U-shape of neural folds in tangential view was 




Presenting of completely fused neural tube was recorded as score 4. When the embryo 
presented a rams head in lateral view, it was recorded as score 5. 
2. Midbrain: 
Presenting of only neural plate was recorded score 0. Presenting a V-shape of neural 
folds in tangential view was recorded score 1. The edge of the neural tube became 
closer and presenting a U-shape of neural folds in tangential view was recorded as 
score 2. Score 3 was given when the neural folds partially fused. Presenting of 
completely ftised neural tube was recorded as score 4. When the prosencephalon was 
divisible into two parts, it was recorded as score 5. 
3. Hindbrain: 
Presenting only neural plate was recorded score 0. Presenting a V-shape of neural 
folds in tangential view was recorded score 1. The edge of the neural tube became 
closer and presenting a U-shape of neural folds in tangential view was recorded score 
2. Score 3 was given when the neural folds fused with an open anterior neuropore. 
Presenting of closure of anterior neuropore was recorded as score 4. When a dorsal 
flexion develops in the pontine region of the neural tube with transparent roof of 4出 
ventricle, it was recorded as score 5. 
Scores of brain development of each embryo were assessed. Mean and standard 
deviation of fore-, mid- and hind brain were calculated separately. Embryos with brain 
score below the average were defined having cranial NTD. The incidence of cranial 
NTD between study and control groups were compared by Chi Square Test. Statistic 
significance was defined as p value <0.05. 
3.6 Establishment of cranial NTD by D-glucose 
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3.6.1 Dosage of D-glucose to induce cranial NTD 
D-glucose at concentrations between 1 - 6 mg/ml (i.e. 6.8mmol/L to 33mmol/L which 
resembles the hyperglycaemic environment in diabetic patients) was examined to 
define the most teratogenic levels on mouse embryos {Table 3. L). 
Table 3.1 Testing dosages of D-glucose to induce hyperglycemia in mouse embryos 
D-glucose 
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Fig. 3.2 Incidence of cranial NTD in mouse embryos induced by hyperglycemia 
D-glucose at 4mg/ml in the rat serum significantly induced cranial NTD in the mouse 
embryos (Fig. 3.2, Table 3.2). The incidence of induced cranial NTD was as high as 
95.2%. This dose was comparable to clinical blood glucose level in DM patients. 
Therefore, 4mg/ml D-glucose was used to induce hyperglycemia to study the potential 
protective effect of Maidong in vitro. 
3.7 Experimental designs 
Three experiments were designed in this study to explore the potential protective 
effect of Maidong on hyperglycemic-induced cranial NTD. Experimental design in 




3.8 Part I: Efficacy and dose-response effects ofMaidong extract 
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Fig. 3.3 Efficacy and dose-response effects ofMaidong extract 
To establish the potential efficacy and to determine the minimum effective dose of 
Maidong extract in preventing cranial NTD. Maidong extract at ascending dosage was 
supplemented to the developing mouse embryos directly into rat serum under 
hyperglycemic condition (4mg/ml D-glucose) in vitro (Fig. 3.3). 
3.8.1 Safety dose ofMaidong extract on non-diabetic mouse embryos 
3.8.1.1 Dosage 
Before testing the possible protective effect of Maidong extract, the potential 
embryotoxicty ofMaidong extract on embryo development was studied firstly. 
Dose for mouse embryos was calculated with the reference to the usual clinical 
dosage of human (Ix clinical dosage) recorded in Chinese Medicine Pharmacopeia 
2010 (CMP, 2010). Testing dosages ofMaidong for mouse embryos were calculated 
in ratio to the clinical dosages in human based on the differences of body scale by the 
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recommended formula from the Food and Drug Administration (FDA) (Gu Y et al., 
2010). The formula was recorded as: 
dm = dhXRm/Rh X(Wh/Wm 严 . 
In this formula, "d" refers to "dosage"; “R” refers to "body factor"; "W" refers to 
"body weight", "m" refers to “adult mouse"; "h" refers to "adult human". The body 
size factor is 59 for mouse while 100 for human. The standard clinical dosage of raw 
herb Maidong recorded in Chinese Medicine Pharmacopoeia 2010 edition ranges from 
6 to 12g person/day. The body weight of pregnant women was assumed as 60kg at 
early gestation. The dosage for mouse was calculated based on the maximum dosage 
for human administration, which was 12g/day/person (60kg). The average body 
weight of the non-diabetic adult female ICR mice we used was 30g. Therefore, the 
dosage of raw herb Maidong for mouse was calculated as follow: 
Wh =60kg, Wm =30g, Rh =100，R^ =59, 4 = 1 , 
dm = 4xRm/Rh X(Wh/Wm)"3 
=12g/60kg X 59/100 x (60kg/30g)^^^ 
=1.5mg/g 
On the basis of above calculation, to be equivalent to human clinical dosage, daily 
clinical dose of raw herb Maidong for a pregnancy mouse was 45mg/30g (1.5mg/g). 
Since Ig Maidong extract was equivalent to 3g raw herb, Ix clinical dose of Maidong 
extract for a pregnancy mouse was 15mg/30g (0.5mg/g). To test the safety of 
Maidong extract in mouse embryos, we started with a higher clinical dose. Therefore, 
in this experiment, Maidong extract at a concentration of 2mg/ml was firstly tested. 
After that, more concentrations were employed by serially diluting the dosage of 
2mg/ml. Hence, descending doses from the 2mg/ml down to 0.06mg/ml were 
employed in this study. 
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Table 3.3 Testing dosages of Maidong extract for embryotoxicity study 
Maidong 
Dosage 0.00 0.06 0.12 0.18 0.24 0.30 0.36 0.42 0.48 1.00 2.00 
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Fig. 3.4 Embryotoxicity at different dosages of Maidong extract. The yellow area in 
the chart stands for the percentage of embryos with normal neural tube. The blue area 
stands for the percentage of embryos with cranial NTD. * p<0.05, between study 
group and control group. 
Maidong extract at or below 0.24 mg/ml were safe for the mouse embryos without 
inducing malformation (Fig. 3.4’ Table 3.4). Although 1 out 14 embryos was found 
having malformation at the dose of 0.24mg/ml, there was no statistically significant 
difference. Therefore, Maidong extract at dosages of 0.06 mg/ml, 0.12 mg/ml, 0.18 
mg/ml and 0.24 mg/ml were examined in the further efficacy study. 
3.8.2 Efficacy and dose-effect response of Maidong extract on non-diabetic 
mouse embryos 




4mg/ml to produce a hyperglycemic environment sufficient to induce cranial NTD in 
the mouse embryos (positive control). Maidong extract at safety dosages as stated 
above, ascending from 0.06mg/ml to 0.24mg/ml, were supplemented to the embryos 
in culture medium with D-glucose to determine the possible protective effect and 
dose- response effect of Maidong extract on the embryos under hyperglycemic 
condition (study group). Non-diabetic full rat serum without D-glucose and Maidong 
extract were used to cultivate the embryos as negative control (Table 3.5). 
3.8.2.1 Dosage and grouping 
Table 3.5 Testing dosages of Maidong extract for efficacy test 
Negative Positive 
Group Control Control Study Group 
Group Group 
Concentration of 
D-glucose 0 4 4 4 4 4 
(mg/ml) 









Control Control Study Group 
Group Group 
Concentration 
of D-glucose 0 4 4 4 4 4 
(mg/ml) 
Dosage of 
Maidong 0 0 0.06 0.12 0.18 0.24 
(mg/ml) 
Total No. of 21 21 21 21 21 21 
tested embryos 
No. embryos 
developed 0 21 4 8 5 7 
cranial NTD 
Incidence of 
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Fig. 3.5 Efficacy of Maidong extract in preventing hyperglycemia-induced cranial NTD. 
The yellow area in the chart stands for the percentage of embryos with normal neural tube. 
The blue area stands for the percentage of embryos with cranial NTD. *p<0.05, between 
study group and positive control group. 
Maidong extract at all of the 4 tested dosages, 0.06mg/ml, 0.12mg/ml, 0.18mg/ml and 
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0.24mg/ml, significantly attenuated the cranial NTD in mouse embryos which was 
induced by hyperglycemia (Fig. 3.5, Table 3.6). At the concentration of 0.06mg/ml, 
the incidence of cranial NTD significantly decreased from 100% to 19%. At the 
concentration of 0.18mg/ml, the incidence of cranial NTD was decreased to 23.8%. 
At the concentration of 0.24mg/ml, only 33.3% of the embryos developed cranial 
NTD. At the concentration of 0.12mg/ml, cranial NTD occurred in 38.1% of the 
embryos. No statistic significance was found in the reduced incidence of cranial NTD 
amongst study groups. No dose-response effect was determined. 
3.9 Part II: Efficacy and dose-response effects of serum from Maidong 
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Fig. 3.6 Efficacy and dose-response effects of Maidong extract-treated rat serum 
Due to drug metabolism, the efficacy of active drug components absorbed into the 
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maternal circulation might be different from the original Maidong extract. Serum 
from Maidong extract-treated rat was used as the culture medium to cultivate the 
embryos under hyperglycemic conditions (Fig. 3.6). 
3.9.1 Preparation of Maidong-treated non-diabetic full rat serum 
3.9.1.1 Rats 
Non-diabetic female Sprague-Dawley (S/D) rats used in Part II experiment were 
obtained from the LASEC CUHK as well. The animal research ethics and care 
guidelines for S/D rats are the same as ICR mouse which was described in 3.1.2. 
3.9.1.2 Dosage for feeding 
All rats were fed by different dosages calculated from usual clinical dosage of human 
(Ix clinical dosage) recorded in Chinese Medicine Pharmacopeia 2010 (CMP, 2010). 
Testing dosages of Maidong in rats were calculated in ratio to the clinical dosages in 
human based on the differences of body scale by the recommended formula from the 
Food and Drug Administration (FDA) (Gu Y et al.，2010). The formula was recorded 
as: 
dr = dhXRr/Rh X(Wh/WryZ3 
In this formula, "d" refers to "dosage"; “R，，refers to "body factor”； "W" refers to 
"body weight’，, "r" refers to “rats，，； "h" refers to "human". The body size factor is 90 
for rat while 100 for human. The standard clinical dosage of raw herb Maidong 
recorded in Chinese Medicine Pharmacopoeia 2010 edition ranges from 6 to 12g 
person/day. The body weight of pregnant women was assumed as 60kg at early 
gestation. The dosage for rats was calculated based on the maximum dosage for 
human administration, which was 12g/day/person (60kg). The average body weight of 
41 
Y Tong 
the non-diabetic adult female S/D rats we used was 375g. Therefore, the Ix clinical 
dosage of raw herb Maidong for rats was calculated as follow: 
Wh =60kg, Wr =375g, Rh =100，Rr =90, 4 = 1 , 
dr = dhXRr/Rh X(Wh/Wr)lZ3 
=12g/60kg X 90/100 X (60kg/375g)"3 
=0.98mg/g 
On the basis of above calculation, Ix clinical dose of raw herb Maidong for every 
gram of rat was 0.98mg. Since Ig Maidong extract was equivalent to 3g raw herb, Ix 
clinical dose of Maidong extract for every gram of rat was 0.327mg. 
3.9.1.3 Administration 
3.27g Maidong extract was dissolved into 50ml boiled autoclaved distilled water to 
make a decoction to feed the rats. The well mixed decoction was cooled down to 
room temperature before administration. 0.5ml decoction was administrated to every 
lOOg rat as Ix clinical dosage. Up to 3x clinical dose of Maidong decoction was 
administrated to different group of rats. All non-diabetic S/D rats were fed orally via a 
20 gauge sterilized gastric tubule (Braintree Scientific, Inc., Boston, USA) once daily 
at 10am in the morning after calculating the feeding volume based on their body 
weights. The course of administration of Maidong decoction was lasted for 
consecutive 14 days (one course of clinical regime in Chinese medicine practice 
usually lasts for 14 days). 
3.9.1.4 Termination of rats and preparation of rat serum 
The Maidong-treated non-diabetic female rats were sacrificed after 14 days fed with 




ether. Collected blood was centrifuged at 3000 rpm for 5 min immediately, and then 
centriftiged one more time after 30 minutes. Full serum was separated from blood 
cells and other components by sterilized pipette, and then stored in -20°C prior to 
further use. Each time before experiment, the Maidong-treated rat serum was 
heat-treated at 56°C for 30 minutes to inactivate the complements. Then, it was 
blown by nitrogen for 1 hour to remove the possible residue of ether. After that, 
D-glucose powder with or without Maidong extract was dissolved into it and well 
mixed before using to cultivate the embryos. 
3.9.2 Safety dose of Maidong-treated non-diabetic full rat serum non-diabetic 
mouse embryos 
Before testing the possible protective effect of Maidong-treated non-diabetic flill rat 
serum, the potential embryotoxicity of Maidong-treated rat serum on embryo 
development was tested firstly. 
3.9.2.1 Dosage 
Serum from 3x clinical dose of Maidong extract-treated non-diabetic rats was diluted 
with normal ftjll rat serum to 2.5x, 2x, 1.5x, Ix, and 0.5x clinical doses and then 
supplemented as the culture medium to cultivate the non-diabetic mouse embryo to 
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Fig. 3.7 Embryotoxicity of Maidong-treated rat serum. The yellow area in the chart 
stands for the percentage of embryos with normal neural tube. The blue area stands 
for the percentage of embryos with cranial NTD. * p<0.05, between study group and 
control group. 
The safety dosage of Maidong fell between 0.5x and 1.5x clinical dosage after 
metabolized (Fig. 3.7，Table 3.7). The data showed that, after being metabolized, 
equal or lower than 1.5x clinical dosage of Maidong has no adverse effect on the 
normal embryo development, while at 2x clinical dosage, it significantly induced 
congenital malformation on normal embryos. Based on these results, Maidong-treated 
non-diabetic full rat serum at 0.5x, Ix, 1.5x clinical dosages were considerable safe 
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and employed in the further efficacy study. 
3.9.3 Protective effect of Maidong extract-treated full rat serum 
3.9.3.1 Dosage and grouping 
According to the result of embryotoxicity test stated in 3.7.2.1，Maidong 
extract-treated non-diabetic full rat serum at 0.5x, Ix and 1.5x clinical dosage was 
safe to culture the non-diabetic mouse embryos without causing any congenital 
anomalies. Therefore, Maidong-treated non-diabetic full rat serum at these 3 doses 
were used as the culture medium to cultivate the embryos under hyperglycemic 
conditions (with 4mg/ml D-glucose solution) to determine the possible therapeutic 
effect and dose-effect response on the non diabetic mouse embryos (Table 3.8). 
Table 3.8 Testing dosages of Maidong-treated rat serum for efficacy study 
Negative Positive 
Group Control Control Study Group 
Group Group 
Concentration 
of D-glucose 0 4 4 4 4 
(mg/ml) 
Clinical 






Table 3.9 Efficacy of Maidong-treated rat serum in preventing hyperglycemia-induced 
cranial NTD 
Negative Positive 
Group Control Control Study Group 
Group Group 
Concentration 




Maidong Ox Ox 0.5 x 1 x 1.5 x 
-treated serum 
Total No. of 
tested 18 18 18 19 18 
embryos 
No. of 
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Fig. 3.8 Efficacy of Maidong-treated rat serum in preventing hyperglycemia-induced 
cranial NTD. The yellow area in the chart stands for the percentage of embryos with 
normal neural tube. The blue area stands for the percentage of embryos with cranial 
NTD. * p<0.05, between study group and positive control group. 
The results of efficacy study showed that, after being metabolized, Maidong extract 
still had a protective effect to significantly attenuate the congenital cranial NTD 
induced by hyperglycemia (Fig. 3.8, Table 3.9). No statistic significance was found in 
the decreased incidence of cranial NTD amongst study groups. No dose-response 
effect was determined. 
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3.10 Part III: Efficacy and dose-response effects of Ophiopogonin D, a major 
chemical component of Maidong in preventing hyperglycemia-induced cranial 
neural tube defect 
D-glucose ICR mouse Maidong f Ophiopogonins / A, B, C, D (Rucosgenin) 
embryos extract J 
(E7-5) [ _ _ _ _ ] ) [ B: C, D' (Diosgenin) 
「 M d l 
、 + Z Polysaccharides ^ 
l ^ g g l l M d 2 
O2 48hrs 
CO2 
i ^ t h e r components 
ICR mouse 
embryos (E9.5) 
Fig. 3.9 Efficacy and dose-response effects of Ophiopogonin D, a major chemical 
component ofMaidong 
To determine whether the major chemical components of Maidong (Ophiopogonins 
and polysaccharides) have any protective effect on hyperglycemia-induced 
embryopathy, purified medicinal compounds isolated from Maidong were used. 
Ophiopogonins and polysaccharides are two main chemical components of Maidong 
which may contribute the therapeutic effect of glycaemic control (Yang MP et al., 
2008). Ophiopogonins consists of components ophiopogonin A, B, C and D which 
belong to Ruscogenin, and ophiopogonin B,，C，，D，which belong to Diosgenin. 
Md-1 and Md—2 are the two known polysaccharides in Maidong (Yang MP et al., 
2008). 
Therefore, ophiopogonins (A, B, C, D, B,，C，，D') alone and polysaccharides (Md-1, 
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Md-2) alone were planned to use to cultivate mouse embryos under the 
hyperglycemic condition (4mg/ml D-glucose) as in Part I to observe the potential 
protective effect of each component. Ophiopogonin D, one of the major chemical 
components, was the first Maidong active compound to be tested in this thesis. 
3.10.1 Safety dose of Ophiopogonin D 
Before studying the efficacy of Ophiopogonin D in preventing 
hyperglycemia-induced cranial NTD, the embryotoxicity of this compound was 
tested. 
3.10.1.1 Preparation of Ophiopogonin D 
The pure compound of Ophiopogonin D was provided by Tauto Biotech (PR. China). 
The product analysis by HPLC shows the purity of this compound is equal or over 
98%. 
3.10.1.2 Dosage 
It was reported that about 336mg Ophiopogonin D could be isolated from 10kg 
Maidong raw herb through water extraction (Zhou YH et al., 2002). Based on this 
ratio, Ophiopogonin D was calculated from the effective dosage of Maidong extract 
(Ig Maidong extract = 3g Maidong raw herb) examined in Part I study as follow: 
0.06mg/ml x (336mg/10kg)/3 = 0.672ng/ml 
0.24mg/ml x (336mg/10kg)/3 = 2.688ng/ml 
Therefore, in this part of study, Ophiopogonin D at descending dosages from 3ng/ml 
to 0.25ng/ml were supplemented to the embryos in non-diabetic ftill rat serum with 
D-glucose to determine the possible embryotoxicity on the non-diabetic mouse 
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embryos (Table 3.10). 
Table 3.10 Testing dosages of Ophiopogonin D for embryotoxicity study 
Dosage of 
Ophiopogonin D 0 0.25 0.5 1 1.5 2 2.5 3 
(ng/ml) 
Relevant dose of 
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Fig. 3.10 Embryotoxicity of Ophiopogonin D. The yellow area in the chart stands 
for the percentage of embryos with normal neural tube. The blue area stands for the 
percentage of embryos with cranial NTD. *p<0.05, between study group and control 
group. 
The results showed that Ophiopogonin D at a dosage equal or lower than 1.5ng/ml 
had no adverse effect on the normal embryo development (Fig. 3.10, Table 3.11). 
Though 21.4% malformed embryos were observed at the concentration of 1.5ng/ml, 
the severity was not statistically significant. The dosage of Ophiopogonin D equal or 
higher than 2ng/ml significantly induced congenital malformation on normal embryos. 
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Based on these, Ophiopogonin D at 0.25ng/ml, 0.5 ng/ml, 1 ng/ml and 1.5 ng/ml were 
examined in the efficacy study. 
3.10.2 Efficacy and dose-response effects of Ophiopogonin D 
3.10.2.1 Dosage and grouping 
Based on the result of embryotoxicity test on Ophiopogonin D stated above, 
Ophiopogonin D at ascending dosages from 0.25ng/ml to 1.5ng/ml were 
supplemented to the embryos in rat serum with D-glucose to determine the possible 
therapeutic effect on the embryos (Table 3.12). 
Table 3.12 Testing dosages of Ophiopogonin D for efficacy study 
Negative Positive 
Group Control Control Study Group 
Group Group 
Concentration of 
D-glucose 0 4 4 4 4 4 
(mg/ml) 
Dosage of 





Table 3.13 Efficacy and dose-response effects of Ophiopogonin D 
H Positive 
Control Study Group 
Group 
D-glucose 0 4 4 4 4 4 
(mg/ml) 
Dosage of 
Ophiopogonin D 0 0 0.25 0.5 1 1.5 
(ng/ml) 
Total No. of 20 22 4 18 18 18 
tested embryos 
No. of embryos 
developed 0 22 4 5 7 11 
cranial NTD 
Incidence of 0 100 100 27.8 38.9 61.1 
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Fig. 3.11 Efficacy and dose-response effects of Ophiopogonin D. The yellow area in 
the chart stands for the percentage of embryos with normal neural tube. The blue area 
stands for the percentage of embryos with cranial NTD. * p<0.05, between study 
group and positive control group. 
The results of efficacy test indicated Ophiopogonin D significantly attenuated the 
hyperglycemia induced cranial NTD at dosages ranged from 0.5ng/ml to 1.5ng/ml 
(Fig. 2.11, Table 3.13). At the dosage of 0.5ng/ml, there was the lowest incidence of 
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cranial NTD in mouse embryos. Lower than this dosage, no protective effect was 
observed. At higher doses, the incidence of cranial NTD in embryos appeared to be 
decreased in response to the increase of the employed doses. However, there was no 
statistic significance found in the decreased incidence of cranial NTD amongst study 





4.1 Whole embryo culture system 
In this study, WEC was employed with the following advantages: 
1. As a major congenital anomaly induced by hyperglycemia, cranial NTD occurs at 
E8 which perfectly lies in this particular developmental window of WEC; 
2. WEC simplifies the maternal environmental condition on the tested embryos and 
then more accurately assesses the potential protective effect of the Chinese 
medicine; 
3. Compared with other culture method, for example Primary cell culture, WEC is 
more suitable to demonstrate the malformation process occurs on the whole 
embryos; and 
4. Compared to in vivo animal experiment, WEC reduces the pregnancy variation 
and saves cost and time. The progress of WEC is much shorter than the in vivo 
experiment. Therefore large number of tested embryos could be employed. 
The limitation of employing WEC in studying diabetic embryopathy is the duration of 
the culture. The whole mouse embryos can only be cultured for maximum 72 hours 
and start at E7.5. It means the embryos have to be harvested on or before El0.5. 
Hence, organogenesis such as development of heart and skeleton structure which 
occur after El0.5 may not be observed by WEC. 
4.2 Quality control of Maidong extract 
Maidong extract used in this study was obtained from PuraPharm International (HK) 
Ltd. It is commonly used and is provided to most local TCM clinics and pharmacies 
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in Hong Kong. Most of the TCM herbs are plants. The quality differs from batch to 
batch due to environmental factors and the efficacy varies when it is prepared by 
different people. Compared to this, the component of the Maidong extract from 
PuraPharm is prepared under GMP standard with a standard manufacturing process. 
The quality and components of the products are more consistent. 
The limitation of using Maidong extract from PuraPharm is that there may be some 
unknown excipients added to the extract during the manufacturing process for 
commercial reason. Therefore, the embryotoxicity of the tested Maidong extract 
presented in our study might be attributed from these excipients instead of Maidong 
extract itself. Hence, to further confirm the embryotoxicity and effective doses of 
Maidong extract from PuraPharm, water extract of Maidong from The institute of 
Chinese Medicine, The Chinese University of Hong Kong (ICM, CUHK) will be 
employed in the future study, as the extraction process of ICM Maidong are well 
known and no excipient is included in the process. 
4.3 Protective effect of single herb, formula and chemical components 
Formula is the most commonly administration of TCM in clinical practice. Each and 
every herb in the formula not only presents its own pharmaceutical effect，but also 
interacted with each other and maximize their efficacy, reduce potential toxicity or 
even may generate a new effect which is absent when use single herb only. For 
instance, an experimental study reported that the level of Ginsenoside changed in 
Radix Ginseng when it was used in the formula with Ophiopogonis Radix and 
achieved a better therapeutic effect in reducing blood glucose level in alloxan-induced 
diabetic mice (Fang L et al., 1998). Therefore, each ingredient in single herb may not 
demonstrate the protective effect of the herb, as well as, each herb in the formula 
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cannot fully elaborate the efficacy of the formula. 
As a single herb, Maidong was still examined as a very first step to initiate the study, 
since the pharmacotoxicity and working mechanism were easy to be clarified than 
formula. Besides, Ophiopogonins D, the major chemical component was also tested to 
specify the protective effect of Maidong. Polysaccharides and Ophiopogonins are two 
major groups of chemical components of Maidong. Both of them were reported 
effective in glycemic control (Yang MP et al, 2008). Ophiopogonins D was selected 
as the first target compound for efficacy test as it is at highest composition in 
Maidong raw herb and could be isolated perfectly with simple manufacturing process. 
4.4 Dosage of D-glucose to induce cranial NTD 
D-glucose at a concentration of 4mg/ml was used in our study to induce 
hyperglycemia and study the potential protective effect of Maidong. The incidence of 
induced cranial NTD at this dosage was as high as 95.2%. D-glucose at 4mg/ml in the 
rat serum could induce cranial NTD in the mouse embryos without causing other 
complicated structural malformations. It was helpful to specify the type of 
malformations and focus the protective effect of Maidong on preventing a major 
congenital malformation in DM complicating pregnancy, cranial NTD. It also helped 
to clarify the same structural malformations due to the potential toxicity of Maidong. 
Besides, the concentration of D-glucose at 4mg/ml was consistent with the effective 
dosage reported by other studies (Styrud J & Eriksson UJ, 1992). 
4.5 Dosage and efficacy of Maidong extract and Ophiopogonin D 
Maidong extract at descending doses from the 0.24 mg/ml to 0.06mg/ml were safe for 
embryogenesis. It is hard to relate these doses to the in vivo doses for the mother mice 
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since the metabolism of the drug in animal is very complicated. There are not enough 
pharmacokinetic data to indicate which organ or which part of the body may 
distribute higher concentration of the targeting drug. There is even no 
pharmacokinetic data to identify the bioavailability of Maidong and its components in 
utero. By very rough estimation, we assume only less than 2-3% of Maidong could be 
transferred to the embryos in utero after maternal exposure. The maximum safety 
doses of Maidong at 0.24mg/ml is 5 time higher than the estimated Maidong Ix 
clinical dose in embryos in utero. It indicates that Maidong within the clinical dose 
should be safe for embryo development. 
According to the calculation in 3.10.1.2, the effective dosages of Maidong extract to 
prevent hyperglycemia-induced cranial NTD in vitro was 0.06mg/ml to 0.24mg/ml, 
which were equivalent to the estimated Ophiopogonin D concentrations ranged from 
0.67 to 2.69ng/ml. In the last part of our study, the effective dosage of Ophiopogonin 
D to prevent the hyperglycemia-induced cranial NTD in vitro was 0.5 to 1.5ng/ml, 
this dose range is within the estimated Ophiopogonin D concentrations equivalent to 
the effective dosages of Maidong extract. To confirm the effective dose of Maidong 
and its component, concentrations of Maidong and its components in maternal 
circulation and embryos should be studied in vivo and quantified by HPLC analysis in 
future. 
4.6 Administration of Maidong extract to non-diabetic female rats 
Maidong decoction at 3x clinical dose was orally administrated to all the rats then 
diluted with normal serum to different clinical dose. The course of administration of 
Maidong decoction was lasted for consecutive 14 days to maintain the effective dose 
of the Maidong in bloodstream for the protective effects. 
61 
Y Tong 
The Maidong extract after digestion and metabolism still has a protective effect to 
attenuate the congenital cranial NTD induced by hyperglycemia. At Ix clinical dosage, 
it achieved the best protective effect. Although this effective dosage could not be 
simply relevant to the dosage in Part I and Part II studies, it confirmed the efficacy of 
Maidong after metabolism and indicated the feasibility of examine the protective 
effect of Maidong in in vivo study in future study. Moreover, the concentrations of 
Maidong and its metabolites remained in the treated rat serum could be quantified by 
HPLC to determine the relevant effective doses of Maidong and its active components 





Maidong extract at concentrations ranged from 0.06 to 0.24mg/ml, Maidong 
extract-treated serum at 0.5 to 1.5x clinical dose and Ophiopogonin D at 
concentrations ranged from 0.5 to 1.5ng/ml can significantly reduce the incidence of 
hyperglycemia-induced cranial neural tube defect in mouse embryos in vitro. It 
suggests that Maidong may have protective effects on the hyperglycemia-induced 
congenital anomalies in vitro. Detailed pharmacological studies are required to 





In the future, we will conduct a serial of experiments to confirm the protective effect 
of Dwarf Lilyturf Tuber (Maidong) in preventing hyperglycemia-induced cranial NTD 
in mouse embryos. 
Firstly, to exclude the embryotoxicity and to confirm the efficacy of Maidong extract 
from PuraPharm, Maidong extract from ICM, CUHK will be employed as the 
reference drug for the safety dosage to embryo development and effective dosage in 
preventing hyperglycemia-induced cranial NTD in mouse embryos. Besides, more 
chemical components of Maidong other than Ophiopogonin D will be examined in the 
future study to specify the protective effect of active component of Maidong. 
HPLC techniques will be used to determine the quantity of each major component in 
the Maidong extract-treated serum to elaborate how many Maidong extract was 
remained in the bloodstream after metabolism and which chemical components are 
still preserved. In addition, it will help to determine the effective doses of Maidong 
extract and it chemical components in vitro. 
Secondly, molecular studies will be designed to study the mechanism of Maidong 
extract and its major chemical components in preventing hyperglycemia-induced 
cranial NTD. Our study will mainly focus on the teratogenic pathways which lie in 
oxidative stress and alteration of the arachidonic acid and PGE2 levels in the body. 
Profound study will be conducted to examine whether the possible protective effect of 
Maidong and its chemical components lie in controlling the blood glucose level on 
diabetic mothers or in regulating the expression of key gene or protein which regulate 
the neural tube closure in the embryo. 
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In vivo study will be also involved in our future plan. DM complicating pregnant 
mouse model with significant cranial NTD will be established. Maidong extract and 
its chemical components will be administered to the DM complicating pregnant mice 
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